These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36523777)

  • 21. In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.
    Tanaka A; Kida K; Matsue Y; Imai T; Suwa S; Taguchi I; Hisauchi I; Teragawa H; Yazaki Y; Moroi M; Ohashi K; Nagatomo D; Kubota T; Ijichi T; Ikari Y; Yonezu K; Takahashi N; Toyoda S; Toshida T; Suzuki H; Minamino T; Nogi K; Shiina K; Horiuchi Y; Tanabe K; Hachinohe D; Kiuchi S; Kusunose K; Shimabukuro M; Node K
    Eur Heart J; 2024 Nov; 45(42):4482-4493. PubMed ID: 39215531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
    Mohebi R; Liu Y; Piña IL; Prescott MF; Butler J; Felker GM; Ward JH; Solomon SD; Januzzi JL
    J Am Coll Cardiol; 2022 Oct; 80(16):1529-1541. PubMed ID: 36229089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study.
    Chen W; Liu Y; Li Y; Dang H
    ESC Heart Fail; 2021 Oct; 8(5):3783-3790. PubMed ID: 34155812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
    Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
    J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Prescott MF; Butler J; Felker GM; Maisel AS; McCague K; Camacho A; Piña IL; Rocha RA; Shah AM; Williamson KM; Solomon SD;
    JAMA; 2019 Sep; 322(11):1085-1095. PubMed ID: 31475295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
    Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
    JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sacubitril/Valsartan Cannot Improve Cardiac Function Compared with Valsartan in Patients Suffering Nonvalvular Atrial Fibrillation without Systolic Heart Failure.
    Zhu M; Guo J; Qiqike B; Nay X; Dan S; Kuransi A; Hu G; Han Z; Hou D; Aili A; Xia B; Chen P; Bate B; Xie J
    Int Heart J; 2023; 64(6):1032-1039. PubMed ID: 38030290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
    Chen C; Wu X; Li Y; Peng Y
    Ann Palliat Med; 2021 May; 10(5):5455-5461. PubMed ID: 34044572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
    Tashiro K; Kuwano T; Ideishi A; Morita H; Idemoto Y; Goto M; Suematsu Y; Miura SI
    Cardiol Res; 2020 Dec; 11(6):376-385. PubMed ID: 33224383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.
    Du H; Li X; Zhao W; Jiang N
    J Healthc Eng; 2022; 2022():9494981. PubMed ID: 35222898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany.
    Wachter R; Viriato D; Klebs S; Grunow SS; Schindler M; Engelhard J; Proenca CC; Calado F; Schlienger R; Dworak M; Balas B; Bruce Wirta S
    Postgrad Med; 2018 Apr; 130(3):308-316. PubMed ID: 29446691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sacubitril/Valsartan Improves Cardiac Function in Dialysis Patients.
    Armaly Z; Saffouri A; Kordahji H; Hamzeh M; Bishouty E; Matar N; Zaher M; Jabbour A; Qarawani D
    Cureus; 2024 Jun; 16(6):e63360. PubMed ID: 39070454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
    Nordberg Backelin C; Fu M; Ljungman C
    ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Sacrubitril/Valsartan on Clinical Treatment and hs-cTnT and NT-ProBNP Serum Levels and the Left Ventricular Function in Patients with Chronic Heart Failure.
    Gao Y; Xing C; Hao W; Zhao H; Wang L; Luan B; Hou A
    Int Heart J; 2020 Jan; 61(1):1-6. PubMed ID: 31875616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry.
    Correale M; Mallardi A; Mazzeo P; Tricarico L; Diella C; Romano V; Ferraretti A; Leopizzi A; Merolla G; Di Biase M; Brunetti ND
    Int J Cardiol Heart Vasc; 2020 Apr; 27():100486. PubMed ID: 32140553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China.
    Zuo C; Li X; Fan L; Li J; Tian D; Chen C; Li X; Lv Q
    J Clin Pharm Ther; 2022 Oct; 47(10):1539-1547. PubMed ID: 35649528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
    Murphy SP; Prescott MF; Maisel AS; Butler J; Piña IL; Felker GM; Ward JH; Williamson KM; Camacho A; Kandanelly RR; Solomon SD; Januzzi JL
    Circ Heart Fail; 2021 Jun; 14(6):e008410. PubMed ID: 33998243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A clinical randomized trial: Effects of early application of sacubitril/valsartan on ventricular remodeling and prognosis in acute myocardial infarction patients.
    Liu Z; Cui K; Wang G; Jin W; Yao Q; Zhang Y
    Contemp Clin Trials Commun; 2024 Dec; 42():101303. PubMed ID: 39391226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.